Ignite Creation Date:
2024-05-06 @ 3:30 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04654702
Status:
COMPLETED
Last Update Posted:
2021-11-26
First Post:
2020-11-17
Brief Title:
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap
Sponsor:
Hanmi Pharmaceutical Company Limited
Organization:
Hanmi Pharmaceutical Company Limited
Study Overview
Official Title:
A Multi-center Prospective Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap in Patients With Asthma and Perennial Allergic Rhinitis
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigator examines the past prescription patterns and the reasons for the change of prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who will be taking Monterizine capsules to treat allergic rhinitis
After being given Monterizine capsules Investigator evaluates the therapeutic effectiveness and safety for 3 months or 6 months
After being given Monterizine capsules Investigator evaluates the therapeutic effectiveness and safety for 3 months or 6 months
Detailed Description:
A Multi-center Prospective Observational Study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None